Clinical Trials

75 enrolled

Hodgkin Disease

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07432984 2026-02-25

FMT-LUNG

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06356597 2026-02-24

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

33 enrolled

Colorectal Neoplasms

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

33 enrolled

Lymphoma, Follicular

NCT07413354 2026-02-17

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Carcinoma, Hepatocellular

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

37 enrolled

Nasopharyngeal Carcinoma

NCT07370337 2026-01-27

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

50 enrolled

Squamous Cell Carcinoma of External Auditory Canal

NCT05254847 2026-01-20

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

65 enrolled

Biliary Tract Neoplasms

NCT07330037 2026-01-09

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

41 enrolled

NSCLC

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05532319 2025-12-30

FRONT-1

64 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07304258 2025-12-26

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

30 enrolled

Gastric Cancer Peritoneal Metastases

NCT06722183 2025-12-24

FUTURE

33 enrolled

Colorectal Neoplasms

NCT07296705 2025-12-22

HARBOR

25 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT05977673 2025-12-08

FIL_Tisle-HL

28 enrolled

Hodgkin Disease, Lymphoma

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT07264647 2025-12-04

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT07233252 2025-11-18

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

35 enrolled

Genitourinary

Renal Pelvic Carcinoma

NCT05622071 2025-11-17

HESTIA

50 enrolled

Carcinoma, Hepatocellular

NCT06139419 2025-11-17

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

114 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06529523 2025-10-07

Tislelizumab in People With Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

165 enrolled

Extensive Stage Lung Small Cell Cancer

NCT07196540 2025-09-29

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

78 enrolled

Digestive System Neoplasms

NCT06124378 2025-09-24

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

60 enrolled

Colonic Neoplasms

NCT06838208 2025-09-24

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

56 enrolled

Small Cell Lung Carcinoma

NCT04047186 2025-09-23

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

12 enrolled

Lung Neoplasms, Multiple Pulmonary Nodules

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

130 enrolled

Rectal Neoplasms

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

29 enrolled

Head and Neck Neoplasms

NCT05880082 2025-08-24

PPIO-004-EC001

118 enrolled

Esophageal Squamous Cell Carcinoma

NCT07128693 2025-08-19

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT07109401 2025-08-07

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

37 enrolled

Perioperative Immunotherapy

NCT05517330 2025-07-31

neoCHANCE-1

23 enrolled

Head and Neck Neoplasms

NCT07086456 2025-07-25

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05604560 2025-07-23

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

25 enrolled

Adenocarcinoma, Pancreatic Neoplasms

NCT07078305 2025-07-22

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

134 enrolled

Carcinoma, Hepatocellular

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07047586 2025-07-03

LEAF-01

146 enrolled

Carcinoma, Hepatocellular

NCT06977828 2025-06-29

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07031700 2025-06-22

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

22 enrolled

Lymphoma, Follicular

NCT07019181 2025-06-13

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

26 enrolled

Esophageal Neoplasms

NCT05319574 2025-06-12

SACTION01

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05044871 2025-06-08

BRIGHT